<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[2, 13] rosuvastatin monotherapy or in combination with fenofibrate or -3 fatty acids<br>[78, 80] rosuvastatin monotherapy<br>[85, 93] fenofibrate or -3 fatty acids on the lipoprotein<br>[128, 130] rosuvastatin monotherapy<br>[142, 145] rosuvastatin 10 mg/day<br>[147, 148] fenofibrate<br>[159, 162] -3 fatty acids<br></td>
<td width=33%>
[2, 13] rosuvastatin monotherapy or in combination with fenofibrate or -3 fatty acids<br>[75, 80] high-dose rosuvastatin monotherapy<br>[81, 93] moderate dosing combined with fenofibrate or -3 fatty acids on the lipoprotein<br>[128, 130] rosuvastatin monotherapy<br>[142, 148] rosuvastatin 10 mg/day combined with fenofibrate<br>[159, 162] -3 fatty acids<br></td>
<td width=33%>
[2, 16] rosuvastatin monotherapy or in combination with fenofibrate or -3 fatty acids on lipoprotein subfraction<br>[75, 94] high-dose rosuvastatin monotherapy with moderate dosing combined with fenofibrate or -3 fatty acids on the lipoprotein subfraction<br>[109, 114] low-density lipoprotein cholesterol<br>[128, 137] rosuvastatin monotherapy 40mg/day (R group,<br></td>
</tr>
